Intech Investment Management LLC Makes New $598,000 Investment in RxSight, Inc. (NASDAQ:RXST)

Intech Investment Management LLC acquired a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,091 shares of the company’s stock, valued at approximately $598,000.

Other institutional investors have also recently bought and sold shares of the company. CWM LLC increased its position in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of RxSight by 854.1% in the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of RxSight in the second quarter worth $41,000. Amalgamated Bank boosted its holdings in shares of RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after buying an additional 207 shares during the period. Finally, KBC Group NV grew its stake in RxSight by 63.6% in the 3rd quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after buying an additional 479 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,901,070. This trade represents a 6.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Shweta Maniar sold 3,782 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the transaction, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 62,702 shares of company stock valued at $3,059,197. 9.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

RXST has been the subject of several recent analyst reports. Jefferies Financial Group assumed coverage on RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price for the company. Stifel Nicolaus lowered their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company lowered their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Oppenheimer dropped their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $61.63.

RxSight Trading Up 1.0 %

RXST stock opened at $46.88 on Friday. RxSight, Inc. has a 1-year low of $28.88 and a 1-year high of $66.54. The firm has a market cap of $1.89 billion, a PE ratio of -56.48 and a beta of 1.19. The business’s 50-day moving average price is $48.58 and its two-hundred day moving average price is $52.31.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.